Traws Pharma stockholders approve share increase, elect directors at annual meeting

Traws Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 8, 2026 in a virtual format, according to an 8-K filed with the Securities and Exchange Commission. As of the May 18, 2026 record date, there were 15,150,669 shares of Company common stock issued and outstanding and entitled to vote.¹ At the meeting, 8,452,410 shares, or approximately 55.78% of those entitled to vote, were represented by proxy or in person, establishing a quorum.¹

Stockholders elected seven director nominees to serve until the 2027 Annual Meeting: Iain Dukes, D.Phil., Werner Cautreels, Ph.D., Trafford Clarke, Ph.D., John Leaman, M.D., Nikolay Savchuck Ph.D., M. Teresa Shoemaker, and Jack E. Stover.¹

Stockholders also approved an amendment to the company's 2021 Incentive Compensation Plan to increase the number of shares of common stock available for issuance by 2,000,000 and make certain other administrative changes.¹ The vote on that proposal was 4,821,796 in favor to 1,694,075 against, with 6,690 abstentions and 1,929,849 broker non-votes.¹ The amendment became effective on July 8, 2026 following receipt of stockholder approval.¹

Stockholders also ratified KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, by a vote of 7,659,805 in favor to 789,757 against, with 2,848 abstentions.¹

A separate proposal, to approve issuance of shares upon exercise of Series B and Series C Warrants issued under an April 15, 2026 Securities Purchase Agreement, passed 2,270,414 in favor to 151,196 against, with 614,528 abstentions and 1,929,849 broker non-votes.¹ Shares issued to investors under that same purchase agreement were not entitled to vote on this proposal under Nasdaq listing rules.¹

A proposal to allow adjournment of the meeting if needed also passed, but the company did not use it since all other proposals were approved.¹